Basis: FMP quote price / unrounded FMP forward EPS in the trading currency, available after its recorded retrieval time. Source: stored company filings and market data; unavailable inputs remain N/A.
The forward PE ratio is N/A as of 2026-10-06T19:17:42.974Z.
Consensus retrieved: 2026-10-06T14:11:04.862Z. This records retrieval, including cache reads, rather than vendor publication. The calculation uses the separately dated price and estimate available at its as-of time.
Calculation as of: 2026-10-06T19:17:42.974Z.
Quote observation: 2026-10-06T19:15:17.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 11bda5a52c13142378ae00f1a27abc282066b453892c652a9842cb594787c7ab
Forward PE Ratio (N/A) = Dated Quote Price ($1.06) / Consensus Forward EPS ($-0.28)
FORWARD PE RATIO
N/A
MaxCyte, Inc.
Market Cap
$114.08M
Forward PE Ratio
N/A
| NAME | MARKET CAP | FORWARD PE RATIO |
|---|---|---|
| MaxCyte, Inc. (MXCT) | $114.08M | N/A |
| Caribou Biosciences, Inc. (CRBU)vs › | $114.06M | N/A |
| Lucid Diagnostics Inc. (LUCD)vs › | $114.44M | N/A |
| Genelux Corporation (GNLX)vs › | $114.73M | N/A |
| Foghorn Therapeutics Inc. (FHTX)vs › | $113.39M | N/A |
| Unicycive Therapeutics, Inc. (UNCY)vs › | $112.54M | N/A |
| Coya Therapeutics, Inc. (COYA)vs › | $115.88M | N/A |
| BGM Group Ltd. (BGM)vs › | $112.28M | N/A |
| Insight Molecular Diagnostics Inc. (IMDX)vs › | $112.05M | N/A |
| Spruce Biosciences, Inc. (SPRB)vs › | $118.41M | N/A |
Trailing P/E
N/A
reported TTM EPS
Forward P/E
N/A
consensus EPS · fiscal year ending 2026-12-31
At the dated quote price of $1.06, each upcoming fiscal year's consensus EPS implies a different multiple — how quickly the price is "paid down" by expected earnings if the estimates hold.
| Fiscal year end | Consensus EPS | Estimate range | Analysts | Implied P/E |
|---|---|---|---|---|
| 2026-12-31 | $-0.28 | $-0.30 – $-0.27 | 3 | n/m |
| 2027-12-31 | $-0.27 | $-0.28 – $-0.25 | 3 | n/m |
| 2028-12-31 | $-0.20 | $-0.21 – $-0.19 | 1 | n/m |
Source: FMP analyst consensus estimates, refreshed with the daily precompute. "n/m" = the consensus EPS is not positive, so a multiple is undefined. There is no forward P/E history chart here because charting one would require the estimates as they stood in the past, which we do not store — see the trailing P/E history for how the realized multiple has moved.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
